doi: 10.1161/hc5001.100835
(Circulation. 2001;104:3125.)
© 2001 American Heart Association, Inc.
Basic Science Reports |
Application of C1-Esterase Inhibitor During Reperfusion of Ischemic Myocardium
Dose-Related Beneficial Versus Detrimental Effects
From the 2nd Medical Clinic (G. Horstick, O.B., B.B., S.P., H.D., M.H., J.M.), Institute for Neurosurgical Pathophysiology (A.H., O.K.), Institute for Clinical Chemistry (G. Hafner), and Institute for Microbiology and Hygiene (M.L., S.B.), Johannes Gutenberg University, Mainz, and the Department of Immunology (O.G.), Georg-August University, Göttingen, Germany.
Correspondence to Dr Georg Horstick, Johannes Gutenberg University Mainz, 2nd Medical Clinic, Langenbeckstraße 1, 55101 Mainz, Germany. E-mail horstick{at}mail.uni-mainz.de
Background— Complement activation during reperfusion of ischemic myocardium augments myocardial injury, and complement inhibition with C1-esterase inhibitor (C1-INH) at the time of reperfusion exerts marked cardioprotective effects in experimental studies. Application of C1-INH in newborns, however, was recently reported to have dangerous and even lethal side effects. This study addresses the essential role of dosage in studies using C1-INH.
Methods and Results— Cardioprotection by C1-INH was examined in a pig model with 60 minutes of coronary occlusion followed by 120 minutes of reperfusion. C1-INH was administered intravenously 5 to 10 minutes before coronary reperfusion without heparin at a dose of 40, 100, and 200 IU/kg body wt. Compared with the NaCl controls, C1-INH 40 IU/kg reduced myocardial injury (44.1±13.8% versus 76.7±4.6% necrosis of area at risk, P
0.05) and significantly suppressed local C3a and C5a generation. Myocardial protection was accompanied by reduced plasma concentrations of creatine kinase and troponin T. In contrast, no beneficial effects were observed when 100 IU/kg C1-INH was used. Furthermore, application of 200 IU/kg C1-INH provoked severe side effects and coagulation disorders.
Conclusions— When applied at the correct dose, C1-INH significantly protects ischemic tissue from reperfusion damage. However, overly high doses (
100 IU/kg) of C1-INH will provoke detrimental side effects, probably via its procoagulatory action.
Key Words: inhibitors • reperfusion • ischemia • myocardium • myocardial infarction
This article has been cited by other articles:
 |
|
 |
|
  B. Bierbach, M. Meier, W. Kasper-Konig, A. Heimann, B. Alessandri, G. Horstick, H. Oelert, and O. Kempski Emboli Formation Rather Than Inflammatory Mediators Are Responsible for Increased Cerebral Water Content After Conventional and Assisted Beating-Heart Myocardial Revascularization in a Porcine Model Stroke, January 1, 2008; 39(1): 213 - 219. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Shagdarsuren, K. Bidzhekov, Y. Djalali-Talab, E. A. Liehn, M. Hristov, R. A. Matthijsen, W. A. Buurman, A. Zernecke, and C. Weber C1-Esterase Inhibitor Protects Against Neointima Formation After Arterial Injury in Atherosclerosis-Prone Mice Circulation, January 1, 2008; 117(1): 70 - 78. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Banz, O. M. Hess, S. C. Robson, E. Csizmadia, D. Mettler, P. Meier, A. Haeberli, S. Shaw, R. A. Smith, and R. Rieben Attenuation of myocardial reperfusion injury in pigs by Mirococept, a membrane-targeted complement inhibitor derived from human CR1 Cardiovasc Res, December 1, 2007; 76(3): 482 - 493. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Fattouch, G. Bianco, G. Speziale, R. Sampognaro, C. Lavalle, F. Guccione, P. Dioguardi, and G. Ruvolo Beneficial effects of C1 esterase inhibitor in ST-elevation myocardial infarction in patients who underwent surgical reperfusion: a randomised double-blind study Eur. J. Cardiothorac. Surg., August 1, 2007; 32(2): 326 - 332. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. David, K. Markstaller, A. L. Depta, J. Karmrodt, A. Herweling, O. Kempski, M. Geisen, and H. W. Gervais Initiation of high-frequency oscillatory ventilation and its effects upon cerebral circulation in pigs: an experimental study Br. J. Anaesth., October 1, 2006; 97(4): 525 - 532. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Thielmann, G. Marggraf, M. Neuhauser, J. Forkel, U. Herold, M. Kamler, P. Massoudy, and H. Jakob Administration of C1-esterase inhibitor during emergency coronary artery bypass surgery in acute ST-elevation myocardial infarction. Eur. J. Cardiothorac. Surg., August 1, 2006; 30(2): 285 - 293. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Banz, O. M. Hess, S. C. Robson, D. Mettler, P. Meier, A. Haeberli, E. Csizmadia, E. Y. Korchagina, N. V. Bovin, and R. Rieben Locally targeted cytoprotection with dextran sulfate attenuates experimental porcine myocardial ischaemia/reperfusion injury Eur. Heart J., November 1, 2005; 26(21): 2334 - 2343. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Tarnavski, J. R. McMullen, M. Schinke, Q. Nie, S. Kong, and S. Izumo Mouse cardiac surgery: comprehensive techniques for the generation of mouse models of human diseases and their application for genomic studies Physiol Genomics, February 13, 2004; 16(3): 349 - 360. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Inal, B. Schneider, M. Armanini, and J. A. Schifferli A Peptide Derived from the Parasite Receptor, Complement C2 Receptor Inhibitor Trispanning, Suppresses Immune Complex-Mediated Inflammation in Mice J. Immunol., April 15, 2003; 170(8): 4310 - 4317. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. C. Riedemann and P. A. Ward Complement in Ischemia Reperfusion Injury Am. J. Pathol., February 1, 2003; 162(2): 363 - 367. [Full Text] [PDF]
|
|
|
|
|
|
C. de Zwaan, A.H. Kleine, J.H.C. Diris, J.F.C. Glatz, H.J.J. Wellens, P.F.W. Strengers, M. Tissing, C.E. Hack, M.P. van Dieijen-Visser, and W.T. Hermens Continuous 48-h C1-inhibitor treatment, following reperfusion therapy, in patients with acute myocardial infarction Eur. Heart J., November 1, 2002; 23(21): 1670 - 1677. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. E. Hack, C. de Zwaan, W. T. Hermens, G. Horstick, O. Berg, B. Bierbach, S. Petersen, H. Darius, M. Horstick, J. Meyer, et al. Safety of C1-Inhibitor for Clinical Use * Response Circulation, October 29, 2002; 106 (18): e132 - e132. [Full Text] [PDF]
|
|